Introduction {#s0005}
============

Gastric carcinoma (GC) is by far the leading fatal reason for death in developing country [@bb0005], [@bb0010]. Although considerable effort has been directed toward the improvement of chemotherapeutic intervention, the 5-year survival rate of stomach neoplasm patients remains poor partly due to the development of Chemo-resistance, raising an urgent need to seek more effective treatment strategies [@bb0010].

MGAT5 is required in the biosynthesis of β1,6GlcNAc-branched N-linked glycans attached to cell surface and secreted glycoproteins. Amounts of MGAT5 glycan products are commonly increased in malignancies, and correlate with disease progression [@bb0015], [@bb0020], [@bb0025], [@bb0030], [@bb0035]. MGAT5 critically remodels tumor microenvironment to facilitate tumor cell growth and metastasis [@bb0040], [@bb0045]. MGAT5 caused ECM collapse also led to release of glycosyl transferase binding cytokines like VEGF and MMPs, which promote tumor growth and metastasis [@bb0050]. Such an irreplaceable role in cancer growth and metastasis makes MGAT5 an appealing target for cancer therapy [@bb0055], [@bb0060]. However, there is no MGAT5 inhibitor available in clinical to date.

H~2~S has been recognized along with nitric oxide (NO) and carbon monoxide (CO) [@bb0065], [@bb0070]. A number of studies have shown that H~2~S is involved in many physiological and pathophysiological functions [@bb0075], [@bb0080], [@bb0085]. However, the anti-tumor effect of H~2~S has not been widely recognized and the current understanding of molecular mechanisms of H~2~S remains very limited [@bb0090], [@bb0095], [@bb0100]. Hence, we identify H~2~S associated proteins, and discovered MGAT5 as one of the potential targets of H~2~S in gastric carcinoma by previous proteomic study.

This study aims to provide the proof-of-concept for evaluating MGAT5 inhibitors as antitumor agents, and to explore the role of H~2~S inhibits MGAT5, and to demonstrate biological significance to complement pharmacological effects of H~2~S.

Materials and Methods {#s0010}
=====================

Cell Culture {#s0015}
------------

Human gastric cancer cells MKN45 and human normal gastric epithelial cells GES-1 were purchased from American Type Culture Collection (ATCC). Human gastric cancer cells BGC823 and human gastric cancer cells BGC803 were obtained from the Institute of Tongji Hospital Affiliated to Tongji University. All the cell lines used in this study were obtained during 2000 to 2012 and cultured according to the suppliers\' instructions. Cells were checked and confirmed to be mycoplasma-free, and the cells were passaged no more than 25--30 times after thawing. Cell lines were characterized by Genesky Biopharma Technology using short tandem repeat (STR) markers.

cAMP Activity Assay {#s0020}
-------------------

Briefly, 1.0 mL compound and 4.0 ml of cAMP solution or 5.0 ml cAMP dilution buffer were added to 96 well plate. After 10 minutes preincubation at 37°C, an enzyme reaction was initiated by adding 5.0 ml of Bio-HS-Eu (K) (Cisbio International) and the 96 well plate was incubated for 150 minutes at 37°C. To stop the enzyme reaction and detect the remaining substrate, either 10 ml of a 1.0 mg/ml XL665-labeled streptavidin (Cisbio International) solution or dilution buffer was added to the plate. After a 30 mins incubation at RT, the Homogeneous Time Resolved Fluorescence (HTRF) signal was measured using an Envision plate reader (Perkin Elmer).

MGAT5 Activity Assay {#s0025}
--------------------

Briefly, MGAT5 activity was assayed in the separate tube in the absence of MnCl~2~. After incubation at 37°C for 5 hours, the reactions were stopped by heating at 100°C for 3 mins and the samples were centrifuged at 5000 rpm in an Eppendorf tube for 15 min. An aliquot (20 μl) of each sample was applied to ODS C~18~ column to separate the products of MGAT5 from the acceptor substrate by High Performance Liquid Chromatography (HPLC) method. All the samples were assayed in duplicate. The enzyme activities were calculated according to the peak areas of the products and expressed as GlcNAc (pmol) transferred/h/mg protein.

Wound Healing Assay {#s0030}
-------------------

Confluent human gastric cancer cells were starved overnight and were scratched using a pipette tip for the wound healing assay. Markings were drawn on the culture dishes as reference points so as to make sure that the same visual field was photographed at 0 hour and 24 hours. Typically, 8--12 visual fields were chosen randomly in one culture dish. Cells were photographed using an EVOS fl Microscope (Advanced Microscopy Group, Mill Creek, Washington) after incubation, according to the suppliers\' instructions. The outline of the wound area (the area with no cells) was then drawn using Image J software to get the exact pixel coverage of each wound area.

Cell Invasion Assay {#s0035}
-------------------

Transwell chambers (8 μm pore size; Corning Life Sciences, Lowell, MA) were coated with 100 μl of diluted matrigel. 0.6 ml medium containing 20% FBS was added to the lower chambers, and cells suspended in serum-free medium at a density of 1.5 × 10^5^ cells/ml (doubled for invasion) were seeded (0.1 ml) in the upper chambers. Various concentrations of aspirin were added to both of the upper and lower chambers. After cultured for an appropriate time (24 hours), cells were then fixed by cold 95% ethanol, stained by 0.1% crystal violet, and cells that had not migrated were removed from the upper chambers. The remaining cells were photographed. The dye was dissolved in 80 μl of 10% acetic acid, and the absorbance of the resulting solution was measured at 600 nm using a multiwell spectrophotometer.

Western Blotting {#s0040}
----------------

Cell lysates were determined with Bicinchoninic acid (BCA) method, and an equal amount of proteins was separated by SDS--PAGE and then transferred to nitrocellulose membranes. The membranes were blocked with 5% (w/v) non-fat dry milk, followed with overnight incubation at 4°C with the following antibodies which were provided in the [Supplemental Table 1](#ec0025){ref-type="supplementary-material"}. Immunoreactive proteins were detected using ECL Plus (Thermo Fisher Scientific, Waltham, MA), after secondary antibody incubation.

Apoptosis Assay {#s0045}
---------------

Cells were seeded into 35 mm dishes (1 × 10^5^ cells/dish) and treated with NaHS, or PBS. The cells were fixed and analyzed by flow cytometry (FACS) (BD FACS Array Bioanalyzer). Apoptotic cells were stained using the Apo-Alert Annexin V kit (BD Biosciences) before analysis.

Immunofluorescence Staining {#s0050}
---------------------------

Cells were fixed with 4% paraformaldehyde at 4°C for 10 min. After washing and pre-blocking, the cells were incubated at 4°C overnight with antibodies against Monoclonal anti-human c-Jun and Monoclonal anti-human MGAT5, respectively, followed by incubation with the FITC-conjugated secondary antibody (1:50; CST) for 1 hour. DAPI was used for nuclear staining (10 μg/ml in PBS, Invitrogen, Life Technologies). Images were then analyzed by laser confocal microscopy (Leica Sp5 Laser Scanning Confocal Microscope; GE).

RNA Extraction, Quantitative Real-Time PCR {#s0055}
------------------------------------------

Total RNA samples from cultured cells were extracted using Trizol reagent (Invitrogen) according to the manufacturer\'s instructions. The sequences of the primers are listed in [Supplemental Table 2](#ec0030){ref-type="supplementary-material"}. Quantitative real-time PCR (qRT-PCR) was performed using an ABI PRISM 7500 Sequence Detection System (Applied Biosystems). The housekeeping gene glyceraldehyde-3 phosphate dehydrogenase (GAPDH) was used as an internal quantitative control.

Chromatin Immunoprecipitation (ChIP) Assays {#s0060}
-------------------------------------------

The ChIP assay was performed according to the protocol described previously. In brief, after treatment, BGC823, MGC803, and MKN45 cells were treated with 1% formaldehyde for 10 min to crosslink chromatin and protein. The chromatin-protein samples were immunoprecipitated with c-Jun antibody. The immunoprecipitates were then incubated with protein A/G agarose beads. After several washes, the protein--DNA complex was reversed. DNA was purified using phenol-chloroform. The DNA was analyzed by qPCR using primers that were specific for regions spanning the c-Jun binding sites in the promoters of *MGAT5*.

Electrophoretic Mobility Shift (EMSA) Assay {#s0065}
-------------------------------------------

Nuclear extracts were isolated from cells with or without NaHS treatment. Nuclear proteins were mixed with biotin-labeled probes containing the AP-1 consensus sequence and incubated at room temperature for 20 min. The sequences of the biotin-labeled probes are listed in [Supplemental Table 3](#ec0035){ref-type="supplementary-material"}. The protein-DNA mixtures were then separated from the free probe on 6% polyacrylamide gel in a 4°C-cold room for 2 hours in Tris-glycine-EDTA running buffer. The gel was dried, exposed to films, and analyzed by a Phosphor Imager (Amersham Biosciences).

AP-1 Luciferase Reporter Assay {#s0070}
------------------------------

Luciferase reporter assay was performed using a Dual-Luciferase Reporter Assay System (Promega). Luciferase reporters were transfected into cells cultured in 35 mm dishes with or without NaHS treatment as described.

2-Deoxyglucose Uptake {#s0075}
---------------------

Uptake of 2-deoxyglucose by the human GC cell lines BGC823 was measured as previously described after the treatment with NaHS at doses (100 μM) for 24 h. The cells were rinsed with a KRP buffer (128 mM NaCl, 4.7 mM KCl, 1.25 mM CaCl~2~, 1.25 mM MgSO~4~, 5 mM NaH~2~PO~4~, 5 mM Na~2~HPO~4~, and 10 mM HEPES, pH 7.4), containing 0.1% (w/v) BSA and 5 mM glucose every 40 min for a total of 120 min at 37°C. The cells were then treated with 100 nM insulin in a KRP buffer without glucose for 15 min or left untreated. 2-deoxy-D \[^3^H\]-glucose (1 μCi·ml^−1^) was added, and the cells were incubated for 15 min. The cells were rinsed three times in ice-cold phosphate-buffered saline (PBS) containing 10 mM glucose, and they were then lysed with 0.4 N NaOH. ^3^H radioactivity was measured in a liquid scintillation counter (Beckman LS6500). Each sample was measured in triplicate. Nonspecific uptake was determined in the presence of cytochalasin B (10 μM) and was subtracted from each value. A transient treatment (15 min) with 100 nM insulin in the KRP buffer before the cells were treated with radioactive glucose was applied in both the cells cultured with low glucose (5.5 mM, without insulin) and the cells cultured with high glucose (25 mM) with insulin (100 nM). In these experiments, the concentration of insulin applied in the following glucose-uptake assay (including the transient insulin treatment before application of 2-deoxy-d \[^3^H\]-glucose and the insulin contained after application of 2-deoxy-D\[^3^H\]-glucose) was identical to that used in the cell culture period.

XF Bioenergetics Assay {#s0080}
----------------------

Mitochondrial oxygen consumption rate (OCR), extracellular acidification (ECAR) and Fatty acid oxygen (FAO) were conducted using a Seahorse XF24 Analyzer. The cells were seeded in Seahorse 24-well microplates and cultured at 37°C with 5% CO~2~. The following day, the media was replaced with 700 μl assay medium composed of DMEM without FBS and sodium bicarbonate and incubated at 37°C without CO~2~ for 1 hour. The basal OCR and ECAR were measured. To measure cells mitochondrial capacity, drugs were injected to the final concentration as 2 μg/ml of oligomycin, 2.5 μM of carbonylcyanide-ptrifluorometthoxyphenylhydrazone (FCCP) and 2 μM of antimycin A. To measure cells glycolytic capacity, the drug was injected to a final concentration as 11 mM glucose, 20 mM 2-DG.

Co-Immunoprecipitation {#s0085}
----------------------

Cells were collected with NP40 cell lysis buffer. An equal amount of proteins was incubated with antibodies overnight at 4°C. Immunoprecipitates were incubated with protein A/G agarose beads and non-specific proteins were washed away by wash buffer.

Immunohistochemistry {#s0090}
--------------------

Immunohistochemistry (IHC) was performed on tumor sections from human GC cells BGC823 orthotopic Xenotransplantation in nude mice, using antibodies listed in the supplementary materials and methods.

Xenograft Tumor Model {#s0095}
---------------------

This animal study was conducted in accordance with the rules and regulations of the Institutional Animal Care and Use Committee (IACUC) at the Department of Laboratory Animal Science, Fudan University (Shanghai, P.R. China). Male Balb/c nude mice, 4 to 5 weeks old, were purchased from Shanghai SLAC Laboratory Animal Limited Company. Tumor cells at a density of 5 × 10^6^ in 0.2 ml PBS were injected subcutaneously into the stomach of nude mice. The mice were randomly assigned to two groups, control (0.9% saline), NaHS treatment 100 μM/Kg. Body weight of mice was measured individually triple per day. After treatment for two weeks (15 days), mice were sacrificed after the final therapy, and lungs were fixed in 4% paraformaldehyde.

Statistical Analysis {#s0100}
--------------------

Data are presented as the mean--standard deviation. If variances were homogeneous, differences were assessed by one-way ANOVA. Spearman\'s rank test and Fisher\'s exact test were used to analyze clinicopathological correlation. All statistical analyses were carried out using SPSS version 16.0. A two-tailed p-value of \<0.05 was considered as statistically significant. Student\'s t-tests were performed as indicated in the figures. Results were considered significant when *P* \< .05.

Results {#s0105}
=======

H~2~S Downregulates the Expression of MGAT5 and Inhibits its Activity {#s0110}
---------------------------------------------------------------------

MGAT5 is an enzyme that catalyzes the formation of a β1,6-N-acetylglucosamine side chain to a core mannosyl residue in N-linked glycoproteins. Besides its direct function of producing aberrant glycoproteins, it promotes cancer progression by its involvement in the stimulation of oncoproteins in cancer cells [@bb0030], [@bb0105], [@bb0110], [@bb0115], [@bb0120]. It has recently emerged as a promising target for cancer therapy [@bb0060].

In a previous effort to identify the potential targets of H~2~S in gastric carcinoma (GC), we conducted a proteomic study to identify a novel MGAT5 inhibitor. Sodium Hydrosulfide (NaHS) is a donor, which rapidly releases H~2~S. We first found the *MGAT5* gene level and MGAT5 protein level was apparent diminution observed in GC cells treated with NaHS for 24 hours ([Figure 1](#f0005){ref-type="fig"}A, B). Immunofluorescence confocal also show, the expression of MGAT5 was apparent diminution observed in the GC cells treated with NaHS for 24 hours ([Figure 1](#f0005){ref-type="fig"}C). To further confirm the MGAT5 activity inhibitory effect with NaHS treatment, we detected the activity of MGAT5 by HPLC assay with the same amount of protein in GC cells at the same time with NaHS treatment on different concentrations. We found the H~2~S significantly inhibited the activity of MGAT5 in GC cells ([Figure 1](#f0005){ref-type="fig"}D). The aforementioned results suggested the potential function of H~2~S on inhibiting cellular MGAT5 activity in GC cells.Figure 1H~2~S downregulates the expression of MGAT5 and inhibits its activity.(A). After treatment with various concentrations of NaHS for 24 h, cell extracts were prepared and applied to immunoblotting with MGAT5. GAPDH was used as a loading control. (B). quantitative real-time PCR analysis the expression of *MGAT5* mRNA in GC cells after 24 hours with treatment NaHS at various concentrations. (C). Immunofluorescence staining of MGAT5 in GC cells treated with NaHS at 100 μM after 24 hours. (D). The effect of H~2~S on MGAT5 activity inhibition in different cells. Various concentrations of NaHS were added to GC cells. The activity of MGAT5 was determined by the HPLC methods using pyridiylaminated GlcNAc~2~Man~3~GlcNAc~2~ as acceptor substrate in the absence of Mn^2+^. Each bar represents the means ± S.D. of three independent experiments.Figure 1

H~2~S Inhibits MGAT5 Activity Though Specifically Dissociation of KPNA2 With c-Jun Interaction {#s0115}
----------------------------------------------------------------------------------------------

To further establish whether H~2~S exclusively inactivated c-Jun, ETS Proto-Oncogene 1 (ETS-1), Transcription Factors of the Nuclear Factor KB (NF-KB), bHLH Transcription Factor (c-Myc), Hypoxia Inducible Factor 1 alpha subunit (HIF-1 alpha), and Mammalian Target of Rapamycin (mTOR) signaling pathway were evaluated [@bb0120], [@bb0125], [@bb0130], [@bb0135], [@bb0140], [@bb0145], [@bb0150]. In GC cells, the status of c-Jun, ETS-1, NF-KB, c-Myc, HIF-1a remained unchanged after addition of NaHS for 24 hours ([Figure 2](#f0010){ref-type="fig"}A, [Supplementary Figure S2A](#ec0005){ref-type="supplementary-material"}). At the same time, we found the H~2~S promoted an increased cellular level of the cAMP in GC cells by HTRF assay ([Figure 2](#f0010){ref-type="fig"}B). Results suggested the potential function of H~2~S on inhibiting cellular mTOR signaling pathway in GC cells [@bb0150]. Indeed, treatment of NaHS with GC cells led to a dose-dependent inhibition of cellular mTOR signaling pathway by western blot assay ([Figure 2](#f0010){ref-type="fig"}C, [Supplementary Figure S2B](#ec0010){ref-type="supplementary-material"}). Afterwards, we found that the cAMP-dependent inhibition of mTOR signaling pathway could be mediated by upregulated AMPK activation in GC cells ([Figure 2](#f0010){ref-type="fig"}C). Moreover, we found the protein level of KPNA2 was apparent a concentration-dependent diminution observed in the cell extracts from GC cells treated with NaHS for 24 hours ([Figure 2](#f0010){ref-type="fig"}A). After that, we detected the relationship between KPNA2 and c-Jun with NaHS treatment. Co-IP detection show, KPNA2 and c-Jun is interaction each other ([Figure 2](#f0010){ref-type="fig"}D). Afterwards, we found that the c-Jun has no apparent change in the whole cell extracts from GC cells treated with NaHS for 24 hours ([Figure 2](#f0010){ref-type="fig"}A), and that there was a concentration-dependent augmentation of c-Jun in the GC cells cytoplasm, with a progressive diminution in the GC cells nuclei ([Figure 2](#f0010){ref-type="fig"}E). Immunofluorescence confocal show, c-Jun is obviously blocked in the cytoplasm from nuclear with treatment NaHS for 24 hours in GC cells, compared with control ([Figure 2](#f0010){ref-type="fig"}F). We further examined the relationship between H~2~S and AP-1 activity by transfection of DNA constructs containing an AP-1 promoter region into GC cells. As shown luciferase reporter assay, H~2~S significantly augmented AP-1 promoter luciferase activity in GC cells ([Figure 2](#f0010){ref-type="fig"}G). The inhibitory effect of H~2~S on AP-1 binding activation was validated by EMSA, in which the DNA binding capacity of AP-1 in the nuclei extracted from BGC823 and MKN45 cells was attenuated by NaHS treatment for 24 hours ([Figure 2](#f0010){ref-type="fig"}I). ChIP assay further revealed that H~2~S disturbed interaction between c-Jun and its target genes *MGAT5* in GC cells ([Figure 2](#f0010){ref-type="fig"}I). The aforementioned results showed that H~2~S perturbed nuclear translocation and DNA-binding activity of c-Jun might have caused by specifically dissociation of KPNA2 with c-Jun interaction. To test whether the H~2~S abrogated nuclear translocation and DNA-binding activity of c-Jun *via* specifically dissociation of KPNA2 with c-Jun interaction, we examined the impact on migration of BGC823 cells stably expressing KPNA2. We found that KPNA2 overexpression decreased the inhibitory effect on BGC823 cells migration with H~2~S treatment ([Figure 2](#f0010){ref-type="fig"}J). In conclusion, our results demonstrated that H~2~S inhibited MGAT5 activation *via* specifically dissociation of KPNA2 with c-Jun interaction, and repressed the expression of c-Jun downstream targets gene *MGAT5* in GC cells.

H~2~S Suppresses MGAT5-Promoted GC Cells Growth {#s0120}
-----------------------------------------------

First, Flow cytometry analysis demonstrated that NaHS treatment caused a significant increase in the percentage of late apoptotic in GC cells ([Figure 3](#f0015){ref-type="fig"}A). More than that, Western blotting tested that NaHS treatment of GC cells enhanced the expression of BAX, activated caspase-3, two critical proteins indicating cellular apoptosis and suppressed the expression of Bcl-2, the key protein indicating cellular proliferation ([Figure 3](#f0015){ref-type="fig"}B). Bromodeoxyuridine (BrdU) proliferation assay also showed that H~2~S significantly inhibited MGAT5-promoted GC cells proliferation on different concentrations ([Figure 3](#f0015){ref-type="fig"}C). Aerobic glycolysis is a hallmark of cancer, cancer cell get energy quickly through glycolysis, and the intermediate products produced by glycolysis are used for the synthesis of biological macromolecules required for proliferation [@bb0155], [@bb0160], [@bb0165], [@bb0170]. To determine the reason behind this increase in the percentage of the late apoptotic, we next examined cellular metabolism capacity with treated NaHS. We measured ECAR, OCR, and FAO in GC cells treated with NaHS. We found that H~2~S significantly suppressed glycolysis function, ATP production and fatty acid oxidation in GC cells treated with NaHS ([Figure 3](#f0015){ref-type="fig"}D, E, F, [Supplementary Figure S3A](#ec0015){ref-type="supplementary-material"}). The aberrant glycoproteins lead to metabolic reprogramming in cancer cell [@bb0175]. This shift is mediated by an excessive increase in MGAT5 activity, thereby driving the tumor phenotype and promoting tumor growth [@bb0055], [@bb0180], [@bb0185]. We found that H~2~S significantly reduced glucose uptake by 2-deoxyglucose uptake assay in GC cells ([Figure 3](#f0015){ref-type="fig"}G). We also detected the level of ROS by chemiluminescence analysis with the same amount of GC cells protein at the same time with NaHS treatment on different concentrations. We found the H~2~S promoted a decreased cellular level of the ROS in GC cells ([Figure 3](#f0015){ref-type="fig"}H). To test whether the H~2~S suppressed GC cells growth by targeting inhibited the activity of MGAT5, we verification of the impact on glycolysis function, ATP production, and fatty acid oxidation of GC cells stably expressing MGAT5. We found that MGAT5 overexpression decreased the inhibitory effect on GC cells glycolysis function, ATP production, and fatty acid oxidation with H~2~S treatment ([Figure 3](#f0015){ref-type="fig"}D, E, F, [Supplementary Figure S3A](#ec0015){ref-type="supplementary-material"}). These results support our previous observation, indicating that of H~2~S suppresses MGAT5-promoted GC cells growth *in vitro.*

H~2~S Inhibits MGAT5-Promoted GC Cells Migration and Invasion {#s0125}
-------------------------------------------------------------

Metastasis is a major conundrum in Oncotherapy. Cancer cells must invade surrounding tissues and extravasate through the endothelium to blood or lymphatic circulation during the metastasis [@bb0050], [@bb0055], [@bb0060]. We found that H~2~S significantly inhibited MGAT5-promoted GC cells migration and invasion on different concentrations ([Figure 4](#f0020){ref-type="fig"}A, B). Epithelial mesenchymal transition (EMT) is the initial and key step for cancer metastasis. During EMT, cancer cell phenotype changes with a series of proteins, including epithelial and mesenchymal markers [@bb0190], [@bb0195]. Western blot detection indicated that H~2~S significantly downregulated the expression of CD44 while upregulated the expression of E-cadherin from GC cells ([Figure 4](#f0020){ref-type="fig"}C). Meanwhile, MMP-9 and MMP-2 also remarkably downregulated by NaHS treatment from GC cells ([Figure 4](#f0020){ref-type="fig"}C). To testify whether the H~2~S inhibited migration by targeting impaired the activity of MGAT5, we examined the impact on migration of BGC823 cells stably expressing MGAT5. We found that MGAT5 overexpression decreased the inhibitory effect on BGC823 cells migration with H~2~S treatment ([Figure 4](#f0020){ref-type="fig"}D). These results manifested that H~2~S showed migration and invasion inhibitory effects in MGAT5-promoted GC cells.Figure 2H~2~S inhibits MGAT5 activity though specifically dissociation of KPNA2 with c-Jun interaction.(A). After treatment with various concentrations of NaHS for 24 h, cell extracts were prepared and applied to immunoblotting with c-jun and KPNA2. GAPDH was used as a loading control. (B). The cAMP activity was assayed by HTRF. Various concentrations of NaHS were added to GC cells. (C). Western blotting of protein on the mTOR signaling pathway in BGC823 cells after 24 hours with NaHS treatment indicated various concentrations. GAPDH was used as a loading control. (D). Co-Immunoprecipitation detection the relationship between KPNA2 and c-Jun with NaHS treatment after 24 hours in BGC823 and MKN45. (E). Western blotting assayed c-Jun from nuclear and cytoplasmic extracts of GC cells treated with various concentrations for 24 hours. Lamin A and GAPDH was used as a loading control. (F). Immunofluorescence staining of c-Jun in GC cells treated with NaHS at 100 μM after 24 hours. (G). Luciferase reporter assay measuring AP-1 activity in GC cells transiently co-transfected with pAP-1-Luc with NaHS treatment for 24 hours at 100 μM. (H). EMSA assay of DNA binding to AP-1 in the nuclei extracts from BGC823 and MKN45 cells after NaHS treatment for 24 hours at 100 μM. Results are repetitive from at least two independent experiments. (I). GC cells were incubated with NaHS and analyzed by a quantitative ChIP assay with anti-c-Jun antibody. (J). The inhibitory effect of H~2~S on migration of serum free stimulated stably KPNA2 over-expression in BGC823. Each bar represents the means ± S.D. of three independent experiments.Figure 2Figure 3H~2~S suppresses MGAT5-promoted GC cells growth.(A). FACS analysis of apoptosis in GC cells after 24 hours with treatment NaHS at various concentrations. (B). After treatment with various concentrations of NaHS for 24 h, cell extracts were prepared and applied to immunoblotting with apoptosis relevant protein. GAPDH was used as a loading control. (C). BrdU proliferation assay measuring GC cells proliferation capacity with NaHS treatment on various concentrations. Seahorse XF24 Extracellular Flux Analyzer examined the inhibitory effect of H~2~S on cellular metabolism capacity of serum free stimulated stably MGAT5 over-expression in GC cells with NaHS treatment for 200 minutes at 100 μM. (D). Glycolytic Function. (E). Mitochondrial Respiration. (F). Fatty Acid Oxidation. (G). The effect of NaHS solution on 2-deoxtglucose uptake in GC cells. (H). Chemiluminescence analysis assayed the level of ROS in GC cells after 24 hours with treatment NaHS at various concentrations. Each bar represents the means ± S.D. of three independent experiments.Figure 3Figure 4H~2~S inhibits MGAT5-promoted GC cells migration and invasion.(A). Wound healing assayed that the inhibitory effect of H~2~S to migration for serum free stimulated GC cells. Up panel: treatment of H~2~S, the migration capacity was detected. *a*. BGC823, *b*. MGC803, and *c*. MKN45. Down panel: quantification of the inhibition activity of H~2~S on migration. (B). Transwell assayed that the inhibitory effect of H~2~S to invasion for serum free stimulated GC cells. Up panel: treatment of H~2~S, the invasion capacity was detected. *a*. BGC823, *b*. MGC803, and *c*. MKN45. Down panel: quantification of the inhibition activity of H~2~S on invasion. (C). Western blotting assayed EMT relevant protein on GC cells after 24 hours of treatment with NaHS at various concentrations. GAPDH was used as a loading control. (D). The inhibitory effect of H~2~S on migration of serum free stimulated MGAT5 over-expression in BGC823. Each bar represents the means ± S.D. of three independent experiments.Figure 4

H~2~S Inhibits Tumor Growth and Metastasis in Gastric Carcinoma Xenografts {#s0130}
--------------------------------------------------------------------------

To determine whether H~2~S inhibits GC growth and metastasis *in vivo*, we established mice subcutaneous Xenograft tumor model and mice orthotopic Xenotransplantation model with BGC823 cells. When tumors were palpable, mice were randomized to receive either control (Normal Saline) or NaHS by every other daily injection. H~2~S administered at 100 μM/Kg significantly inhibited gastric carcinoma growth both in mice subcutaneous Xenograft tumor model and mice orthotopic Xenotransplantation model, as tumor weight was markedly reduced in NaHS treatment groups compared with control groups in mice subcutaneous Xenograft tumor model ([Figure 5](#f0025){ref-type="fig"}A, C). Notably, the lung metastasis was significantly reduced in mice that received NaHS ([Figure 5](#f0025){ref-type="fig"}A, B). In order to carry out mechanism research, tumor tissues were either prepared for western blot or immunohistochemistry (IHC) analysis. We found H~2~S inhibited MGAT5 expression in high- and low- dose groups by western blot assay ([Figure 5](#f0025){ref-type="fig"}E). IHC analysis also showed that H~2~S significantly reduced MGAT5 level *in vivo* ([Figure 5](#f0025){ref-type="fig"}D). Moreover, we also found the reduction of tumor vascular density and increase the expression of cleaved-caspase-3 in NaHS treatment group ([Figure 5](#f0025){ref-type="fig"}D). Finally, we detected the level of H~2~S in the plasma of mice. Compared with the control group (average 58.526 μM), the treatment group was significantly higher than the control group (average 69.618 μM) ([Figure 5](#f0025){ref-type="fig"}F). Taken together, these data demonstrated that H~2~S is detrimental to the growth and metastasis of gastric carcinoma in the preclinical mice subcutaneous Xenograft tumor model and mice orthotopic Xenotransplantation model.Figure 5H~2~S inhibits tumor growth and metastasis in gastric carcinoma Xenografts.(A). Effect of H~2~S on lung metastasis of human gastric carcinoma cell BGC823 in mice orthotopic Xenotransplantation model. Left. representative bioluminescence imaging of metastatic nodules on lungs. Right. The BGC823 colonies were measured. (n = 3 flanks and 4 mice in each group). (B). Effect of H~2~S on lung metastasis of human gastric carcinoma cell BGC823 in mice orthotopic Xenotransplantation model. Left. representative bioluminescence imaging of metastatic nodules on lungs. Right. HE staining and IHC staining of Ki67 representative photograph of metastatic nodules on lungs. (C). Tumor growth inhibition upon H~2~S treatment in BGC823 gastric carcinoma mice subcutaneous Xenografts tumor model. *a*. The curve of tumor growth after 15-days treatment of H~2~S. *b.* Experimental inhibitory effects of H~2~S on BGC823 Xenografts in nude mice. The percentage of relative tumor volume inhibition values was measured on the last day during the experiment. (D). Effect of H~2~S against primary tumor growth and angiogenesis. A typical photograph of IHC staining of MGAT5, CD31, and cleaved-caspase-3. (E). Inhibition of the expression of MGAT5 in BGC823 mice orthotopic Xenotransplantation model by H~2~S. Mice were humanely euthanized on the last day at 2 hours post-administration of H~2~S and the tumors were resected. Equal amounts of proteins of tumor tissues were evaluated for expression of MGAT5 levels. (F). The level of H~2~S in the plasma of mice orthotopic Xenotransplantation model. Data are shown as means ± S.D. (n = 3 flanks and 4 mice in each group).Figure 5Figure 6The potential toxicity of H~2~S *in vitro* and *in vivo*.(A). Body weight of tumor-bearing mice measured at the indicated times. Apoptotic and metabolism assayed at the indicated concentration by FACS and Seahorse XF24 extracellular Flux Analyzer in human normal gastric cells GES-1. (B). Representative FACS plots and quantitative data of apoptotic rate. Treatment of H~2~S, (C). Glycolysis Function and (D). Mitochondrial Respiration rates were detected. Each bar represents the means ± S.D. of three independent experiments.Figure 6

The Potential Toxicity of H~2~S *In Vitro* and *In Vivo* {#s0135}
--------------------------------------------------------

*In vivo*, we had injected the tumor-bearing mice with a dose of NaHS 100 μM/Kg for 15 days which did not cause their weight loss and death, indicating the safety of H~2~S suppressing the growth and metastasis of BGC823 cells in mice subcutaneous Xenograft tumor model and mice orthotopic Xenotransplantation model ([Figure 6](#f0030){ref-type="fig"}A). *In vitro,* we measured cell apoptosis and metabolism for human normal gastric epithelial cells GES-1 with NaHS treatment. We found that H~2~S has no obvious adverse effects at our therapeutic concentration ([Figure 6](#f0030){ref-type="fig"}B, C, D, [Supplementary Figure S6A](#ec0020){ref-type="supplementary-material"}). In contrast with a high concentration of H~2~S, these data demonstrated that low concentration of H~2~S may have no obvious adverse effects *in vitro* and *in vivo.*

Discussion {#s0140}
==========

H~2~S plays an important role in many physiological and pathophysiological processes in mammals [@bb0080], [@bb0085]. However, the effect of H~2~S on cancer about its development and progression remains largely unclear. We proposed that relatively low concentration of exogenous H~2~S could inhibit GC cells growth and metastasis, which may help us increasingly recognize pharmacological activities of H~2~S, including inhibit growth and metastasis in GC cells. In this study, we identified MGAT5 as one of the potential target of H~2~S and demonstrated H~2~S associated anti-tumor activities, particularly inhibit growth and metastasis, which may help understand the broad anti-tumor function of H~2~S.

Unlike normal cells, MGAT5 overexpress cancer cells were more sensitive to inhibition MGAT5 expression [@bb0055], [@bb0105], [@bb0165], [@bb0190]. As an appealing target for cancer therapy, the efforts for the discovery of MGAT5 inhibitor has not been very successful, the problem is mainly focused on its effectiveness, adverse reactions, and Drug Resistance. It would be interesting to further seek whether this strategy could lead to MGAT5 inhibitor with improved anti-tumor properties.

In summary, our results show that H~2~S may be an important MGAT5 suppressor, inhibits MGAT5-promoted tumor growth and metastasis, both *in vitro* and *in vivo*. Furthermore, there were no obvious adverse effects *in vitro* and *in vivo* at our therapeutic concentration. This study provides new insights for a better understanding of the mechanisms of H~2~S in anti-tumor growth and metastasis effects ([Figure 7](#f0035){ref-type="fig"}). Most safely novel slow-releasing H~2~S donors and H~2~S-releasing hybrid drugs will be designed and applied for further anti-tumor research.Figure 7Hydrogen Sulfide demonstrates promising antitumor efficacy in gastric carcinoma by targeting MGAT5.Schematic illustration of our systems biology approach to identify H~2~S may be an important MGAT5 inhibitor and their corresponding targets. H~2~S specifically dissociation of KPNA2 with c-Jun interaction, and blocking c-Jun nuclear translocation, and downregulation of MGAT5 expression at the level of gene and protein. H~2~S inhibited MGAT5 activity lead to suppress metabolism, substratum focal adhesion turn-over, reduce the expression of exclusively abnormal glycoprotein processes, and disturb cell cyclin. It provides insights into a better understanding of the molecular mechanisms of H~2~S in anti-cancer effects which are required for further application in translational medicine.Figure 7

The following are the supplementary data related to this article.Supplementary Figure S2AAfter treatment with various concentrations of NaHS for 24h, BGC823 cells extract were prepared and applied to immunoblotting with NF-KB, ETS-1, c-Myc, HIF-1 alpha. GAPDH was used as a loading control.Supplementary Figure S2ASupplementary Figure S2BWestern blotting of protein on mTOR signaling pathway in MGC803 and MKN45 cells after 24 hours with NaHS treatment indicated various concentrations. GAPDH was used as a loading control.Supplementary Figure S2BSupplementary Figure S3ASeahorse XF24 extracellular Flux Analyzer examined cellular Non-Glycolytic Acidification, Acute Response, and Non-mitochondrial oxygen consumption in GC cells with NaHS treatment for 24 hours at 100μM. Data are shown as means ± S.D. of three independent experiments.Supplementary Figure S3ASupplementary Figure S6ASeahorse XF24 extracellular Flux Analyzer examined cellular Non-Glycolytic Acidification, Acute Response, and Non-mitochondrial oxygen consumption in GES-1 cells with NaHS treatment for 24 hours at 100μM. Data are shown as means ± S.D. of three independent experiments.Supplementary Figure S6ASupplementary Table 1Supplementary Table 1Supplementary Table 2Supplementary Table 2Supplementary Table 3Supplementary Table 3
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